Language Selector

    Partner Offer for H2020-JTI-IMI2-2020-21 Call

    Published on 25 March 2020
    Author: Nicole Wyss, National Contact Point Health

    A Swedish SME, specialised in biomaterial collection from small airways, is looking to join a consortium for developing an improved SARS-CoV-2 test.

    PExA AB is a Swedish early phase start-up company that develops a technology enabling collection of biomaterial from the small airways with potential in biomarker discovery for early and more precise diagnostics in the field of respiratory medicine.

    The technology  addresses 2 of the 4 topics stated in the scope of the call:

    • development of diagnostics, ensuring rapid evaluation of candidates based on existing technologies
    • development of fast and reliable tools that go beyond the state of the art for detection of COVID-19 carriers and symptomatic individuals suspected of COVID-19 infection

    For more information please contact:

    Jörgen Östling (PhD), CSO
    jorgen.ostling@pexa.se
    www.pexa.se/en